Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

For more than 60 years, Nipro Corporation has been delivering advanced medical products designed to enhance the lives of patients with chronic disease.

In those six decades we have embraced a global vision – the Nipro TRUE range of blood glucose meters are sold in over 70 countries, and our hospital products are trusted in almost 90, creating a brand that is trusted worldwide. Our global business now includes medical devices, pharmaceuticals and medical glass products.

In addition to Nipro branded products, we also provide OEM capabilities – designing and producing custom and private label products for some of the largest healthcare brands in the world. Nipro has 25 manufacturing facilities globally, with another 5 under construction in the Asia Pacific region, and comprehensive capabilities in medical device design and production.

Working closely with healthcare professionals, our global team of more than 15,800 dedicated staff are working towards our mission – delivering products that will enhance and improve the lives of people with chronic disease.

Our Nipro Australia head office is located in St Leonards on the lower north shore of Sydney and was established to meet the growing demand for our products in this region. Our broad and evolving product offering in Australia comprises medical devices in the diabetes, renal, infusion therapy and general hospital areas.



Nipro Diagnostics Inc. first developed a range of blood glucose monitors more than 25 years ago, and continues to research and manufacture our high quality diabetes monitoring products out of facilities in Florida. In Australia we market the TRUE portfolio of blood glucose meters and diabetes consumables, delivering a high quality diabetes monitoring system that is trusted for accuracy, precision and performance.



With over 30 years of continuous research and development in the renal space, Nipro is one of the world’s leading producers of disposable medical equipment for dialysis treatments. In Australia, our expanding range currently includes vascular access devices (safety and standard), bio-hole kits, blood tubing sets, blood line clips and high flux dialysers.



The Nipro Infusion Care program is a comprehensive solution for ambulatory infusion therapy, in the hospital or in the home.  Our Surefuser™+ elastomeric infusion device is a discreet, lightweight infusion device supplied either dry, or pre-filled with prescribed medication and easily connected directly to your patient’s catheter/port.


General Hospital

Our comprehensive range of high quality injection systems is designed for optimal patient comfort and user safety.

 Blood Glucose Monitoring Systems

Research and development for the BGM portfolio is carried out at Nipro Diagnostic Inc. manufacturing facility in Fort Lauderdale, Florida USA. The research and development team is dedicated to developing, designing, and engineering our product portfolio, and continues to explore and evaluate new technologies that can broaden our product portfolio.


Medical Equipment

The Nipro R&D team in Japan and has grown to more than 200 dedicated team members working on innovations in artificial organs, pharmaceuticals, cell culture systems and infusion fluids. Nipro has long been recognised as a leading manufacturer of dialysers, and we continue to our embrace our mission of driving innovation in the dialysis space. Our new powdered dialysates (developed through a high efficacy granulation technology) are now on the market in select countries, and we are nearing the market phase of haemo-diafiltration substitution fluids. Our implanted ventricular-assist devices are currently in clinical testing stage in Japan, and moving forward, our R&D team will target new artificial organs and tissues to become the world’s leading manufacturer in this space.



In the pharmaceutical division our R&D efforts are concentrated on new drugs and formulations in our specialty areas: kidney disease, blood, and nutritional infusion. Projects in development include:

  • Kit products containing drugs, dissolving solution and injection devices.
  • Oral and injection drugs, to expand the generic drug business.
  • Total parenteral nutrition solutions.
  • Cell culture systems into umbilical cord blood stem cells


Manufacturing and Supply-Chain Sophistication

The manufacturing facility has been verified and validated as required by the US FDA Quality System Regulation and has received ISO 13485 certification.